This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q23.9 | Special Copayment Reduction: V147 (rare disease) |
| B. Synonyms | Congenital malformation of aortic and mitral valves, unspecified |
| C. Adult onset | Likelihood of first presentation in adulthood low to moderate — the unspecified code is used when diagnostic subclassification is insufficient; severe cases present in childhood, and mild dysplasia may also be found incidentally in adulthood. |
| 1. History | Q23.9 is used as a provisional classification code at the stage before diagnostic subclassification is made. |
| 2. Causes | Because Q23.9 is an unspecified code, the patient's underlying cause is likely to correspond to one of Q23.0–Q23.8. |
| 3. Genetics | Depending on the specific malformation, NOTCH1, GATA5, NKX2.5, etc. apply; malformation-specific genetic counseling after subclassification. |
| 4. General epidemiology | Because Q23.9 is an unspecified code, the actual prevalence is replaced by the prevalence of the corresponding malformations in Q23.0–Q23.8. |
| 5. Pathophysiology | The general pathophysiology of left heart load from regurgitation or stenosis according to the underlying malformation applies. |
| 6. Symptoms | Symptoms of regurgitation and stenosis according to the underlying malformation; a heart murmur in childhood is often the first clue. |
| 7. Signs | Systolic or diastolic murmur; findings of left ventricular hypertrophy and dilation according to the underlying malformation. |
| 8. Screening | Newborn auscultation and SpO2; echocardiography to evaluate childhood heart murmurs; detailed evaluation to subclassify into Q23.0–Q23.8. |
| 9. Diagnosis | Detailed valve evaluation by echocardiography → subclassification into Q23.0–Q23.8; CMR as an adjunct; diagnostic subclassification is the basis of the treatment plan. |
| 10. Treatment | After subclassification of the underlying malformation, the corresponding treatment guidelines (Q23.0–Q23.8) apply. |
| 11. Prognosis | After subclassification of the underlying malformation, follows the prognosis of that malformation; early subclassification and timely treatment determine prognosis. |
| 12. Prevention | Minimize use of the unspecified code (perform detailed evaluation); after identifying the underlying malformation, apply the corresponding prevention guidelines. |
| 13. References | 10 major clinical guidelines and original papers |
Q23.9 (congenital malformation of aortic and mitral valves, unspecified) is a residual code in the ICD-10 classification system used when a congenital malformation of the aortic or mitral valve has been identified but does not correspond to the specific codes Q23.0–Q23.8, or when evaluation has not been completed so that accurate classification could not be made.
Historically, in the era before echocardiography, detailed anatomical classification of congenital valve malformations was not possible, so the unspecified code was used more frequently. With advances in transthoracic echocardiography from the 1970s, transesophageal echocardiography in the 1980s, and three-dimensional echocardiography and cardiac MRI from the 1990s, detailed anatomical classification of valve dysplasia became possible. In current clinical practice, Q23.9 is mainly used as a provisional code at a stage when the diagnostic process has not been completed, and subclassification into the appropriate code among Q23.0–Q23.8 after complete evaluation is recommended.
Nevertheless, Q23.9 is used in certain situations—gaps in diagnostic information during transfer between pediatric and adult cardiology, provisional classification in outpatient clinics, and administrative and insurance coding purposes. When registering for rare disease Special Copayment Reduction (V147), subclassification into as specific a code as possible is recommended.
The actual underlying causes of dysplasia in patients classified as Q23.9 are the same as those of the malformations corresponding to Q23.0–Q23.8. That is, the cause is an abnormality in the embryonic development of the aortic or mitral valve, which has not been or could not be classified in detail.
Most common underlying dysplasias: bicuspid aortic valve (can be subclassified as Q23.1), congenital aortic valve stenosis (Q23.0), congenital mitral valve dysplasia (Q23.2 or Q23.3), and other valve dysplasias (Q23.8) may be provisionally recorded as Q23.9 before accurate classification.
The embryological mechanisms by cause are the same as in the corresponding entries of Q23.0–Q23.8, including abnormal migration and differentiation of cardiac neural crest cells, gene abnormalities such as NOTCH1/GATA5/NKX2.5, commissural fusion, and abnormal leaflet development.
In patients with Q23.9, subclassification into a specific code as soon as possible through detailed evaluation such as echocardiography or cardiac MRI is important from both clinical and administrative perspectives.
In patients classified as Q23.9, genetic evaluation proceeds with malformation-specific genetic counseling after the actual underlying malformation is identified.
If the final diagnosis is bicuspid aortic valve, testing for related genes such as NOTCH1 and GATA5 and family screening are performed. If congenital mitral valve dysplasia is confirmed, testing for connective tissue disease genes (FBN1, COL5A1, etc.) is considered. When multiple malformations are present or a syndrome is suspected, chromosomal microarray or whole-exome analysis is performed.
At the unspecified stage, the presence of an associated syndrome is first assessed by family history and physical examination, and consultation with a clinical geneticist is considered.
Because Q23.9 is a code used provisionally before diagnostic subclassification, an independent prevalence estimate is not meaningful. The actual underlying malformations of these patients are expected to be distributed among bicuspid aortic valve (most common), congenital aortic valve stenosis, congenital mitral valve dysplasia, and others.
In analyses of administrative databases, the frequency of use of the Q23.9 code can serve as an indicator reflecting the coding accuracy of medical institutions. Q23.9 is used less at specialist cardiac centers that perform detailed anatomical classification and more commonly at non-specialist institutions.
In the Korean rare disease registration system as well, it is recommended that Q23.9 patients be updated to the appropriate specific code through subsequent detailed evaluation.
The pathophysiology of Q23.9 patients is determined by the type of the actual underlying dysplasia. When aortic valve dysplasia predominates, left ventricular pressure overload (stenosis) or volume overload (regurgitation) is the core pathology; when mitral valve dysplasia predominates, elevated left atrial pressure (stenosis) or left ventricular volume overload (regurgitation) is the core pathology.
When stenosis predominates: left ventricular outflow or inflow tract obstruction → left ventricular pressure overload → concentric hypertrophy → diastolic dysfunction → reduced systolic function → heart failure. When regurgitation predominates: systolic regurgitation of blood → left ventricular volume overload → eccentric hypertrophy → diastolic dysfunction → reduced systolic function → progression to heart failure. A mixed pathology may also arise from a combination of these two mechanisms.
Subclassifying from Q23.9 into a specific malformation through detailed evaluation makes it easier to understand the mechanism and establish a treatment plan.
The symptoms of Q23.9 patients are determined by the type and severity of the underlying malformation. The main possible symptoms are as follows.
Neonatal period and infancy: in severe malformations, cyanosis, feeding difficulty, tachypnea, and shock occur. In moderate or greater dysplasia, a heart murmur is heard on auscultation and provides a clue to the diagnosis.
Childhood: exercise intolerance, easy fatigue, and poor growth may occur. Many cases are found without symptoms through a heart murmur at a health checkup.
Adulthood: mild dysplasia is found incidentally at routine adult checkups or on echocardiography performed for other purposes. If moderate or greater, exercise intolerance, dyspnea, and palpitations occur.
Along with accurate symptom assessment, detailed tests are performed to subclassify the underlying malformation.
Physical findings in Q23.9 patients vary according to the underlying dysplasia.
Auscultation findings: a systolic ejection murmur (when stenosis predominates), a diastolic regurgitant murmur (when regurgitation predominates), or a mixed murmur of both is heard. Clues to the underlying malformation can be obtained from the characteristics of the murmur.
Findings of left heart load: when stenosis predominates, findings of concentric left ventricular hypertrophy (sustained apical impulse, systolic thrill) appear; when regurgitation predominates, eccentric left ventricular dilation (laterally displaced apical impulse, hyperdynamic impulse) appears.
ECG and chest X-ray: findings of left ventricular hypertrophy, left atrial enlargement, cardiomegaly, and pulmonary vascular congestion appear according to the type and severity of dysplasia.
In patients provisionally classified as Q23.9, screening and detailed evaluation for accurate diagnosis are the priority.
Newborn screening: if abnormal findings are detected by auscultation and pulse oximetry (SpO2 screening) immediately after birth, echocardiography is performed immediately for accurate diagnosis.
Echocardiography for childhood heart murmurs: abnormal heart murmurs in childhood must be evaluated by echocardiography to identify the underlying malformation and, where possible, subclassified into the appropriate code among Q23.0–Q23.8.
Periodic reassessment: patients provisionally registered as Q23.9 are reassessed by detailed echocardiography or cardiac MRI and updated to a specific code.
In patients classified as Q23.9, accurate diagnostic subclassification is clinically very important.
Echocardiography: two-dimensional, three-dimensional, and Doppler echocardiography are used to evaluate in detail the valve morphology (number of leaflets, commissural status, leaflet motion, annular status, chordal status, papillary muscle status), severity of stenosis or regurgitation, and left ventricular and left atrial size and function. With this evaluation, most cases can be classified into the appropriate code among Q23.0–Q23.8.
Cardiac MRI: an adjunctive role when the echocardiographic window is poor or when anatomical detail is needed.
Cardiac CT: used to evaluate valve calcification, aortic anatomy, and coronary artery anomalies.
Genetic counseling and genetic testing: after diagnostic subclassification, malformation-specific genetic evaluation is performed.
Treatment of Q23.9 patients applies the treatment guidelines for the corresponding specific malformation after accurate diagnostic subclassification.
If subclassified as Q23.0 (aortic valve stenosis), BAV, the Ross procedure, or valve replacement is considered. If subclassified as Q23.1 (bicuspid aortic valve/regurgitation), valve repair or replacement according to regurgitation severity is considered. If subclassified as Q23.2 (congenital mitral stenosis), repair according to anatomical type is performed. If subclassified as Q23.3 (congenital mitral insufficiency), repair based on the Carpentier technique is attempted. If subclassified as Q23.4 (HLHS), staged Norwood-Glenn-Fontan palliative surgery is planned.
Even before diagnostic subclassification, if symptoms are severe or the situation is an emergency, immediate stabilization (PGE1 administration, respiratory support, systemic circulatory support) takes priority.
The prognosis of patients classified as Q23.9 is determined by the actual underlying malformation. Therefore, diagnostic subclassification as early as possible is essential for predicting prognosis and establishing a treatment plan.
In general, with advances in modern cardiology, near-normal life expectancy is achievable for most congenital aortic and mitral valve malformations after timely surgical correction. However, cases on the HLHS (Q23.4) spectrum have a markedly poor prognosis, so distinguishing them early is very important.
The longer the period of provisional classification as Q23.9, the more establishment of an optimized treatment plan may be delayed, so referral to a specialist center and prompt subclassified diagnosis are recommended.
There is no primary prevention for Q23.9 itself; after the underlying malformation is identified, the prevention guidelines for that malformation apply.
Recommendation for code subclassification: minimize use of Q23.9 at the clinical and administrative levels, and subclassify into the appropriate code among Q23.0–Q23.8 through detailed evaluation. This is essential for providing the patient with appropriate treatment and follow-up plans.
Prevention of infective endocarditis: even at the Q23.9 stage, after a dysplastic valve is confirmed, endocarditis prevention guidelines are provided to high-risk patients.
Regular follow-up: after dysplasia is confirmed, progression is monitored by regular echocardiography, and surgery or intervention is planned at the appropriate time.
Family screening: if the underlying malformation is subclassified as bicuspid aortic valve or a familially clustered malformation, echocardiographic screening of first-degree relatives is recommended.
Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for adult congenital heart disease. Eur Heart J. 2021;42(6):563-645. DOI: 10.1093/eurheartj/ehaa554. PMID: 32860028.
Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for Adults with Congenital Heart Disease. J Am Coll Cardiol. 2008;52(23):e143-e263. PMID: 19038677.
Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39(12):1890-1900. PMID: 12084585.
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for Valvular Heart Disease. J Am Coll Cardiol. 2021;77(4):e25-e197. PMID: 33342586.
Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437(7056):270-274. PMID: 16025100.
Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol. 2010;55(25):2789-2800. PMID: 20579530.
Carpentier A, Branchini B, Cour JC, et al. Congenital malformations of the mitral valve in children. J Thorac Cardiovasc Surg. 1976;72(6):854-866. PMID: 993139.
Kalfa D, Butcher J, Bonhoeffer P, Yacoub M. Congenital mitral valve disease: from anatomy to treatment. Prog Pediatr Cardiol. 2012;33(1):45-56.
Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for echocardiographic assessment of native valvular regurgitation. Eur J Echocardiogr. 2013;14(7):611-644. PMID: 23733442.
Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases. Lancet. 2006;368(9540):1005-1011. PMID: 16980116.